carina: cabozantinib post first-line immune-oncology cpi-containing combination in arcc
Published 1 year ago • 104 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
2:19
cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible muc
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
4:15
contact-303: primary pfs analysis of atezolizumab and cabozantinib in ccrcc
-
2:58
phase ii trial of cabozantinib for patients with hcc previously treated with io
-
2:28
breakpoint: cabozantinib after first-line ici in rcc
-
3:29
emerging roles of nivolumab and cabozantinib for renal cell carcinoma
-
1:05
cohort 1 litespark-003: belzutifan cabozantinib 1l treatment for advanced rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
1:26
neoadjuvant cabozantinib in patients with locally advanced non-metastatic ccrcc
-
0:48
phase i/ii trial of adapt-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors
-
4:28
proof: infigratinib as first-line therapy in patients with advanced cca
-
0:39
rationale for targeting fpr2 in female patients with pancreatic cancer
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
1:30
camilla: combining a vegf tki with immune checkpoint inhibitors for ge and gi cancer
-
1:02
breast and gynecological cancer highlights at esmo immuno-oncology 2022
-
0:55
dr. plimack on frontline checkpoint inhibitors in bladder cancer
-
2:24
cytoquest™ cr ctc capture antibody immobilization
-
41:36
ac20 - ccf research fellowship reports part 2
-
3:58
case 4: next-generation sequencing